MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge
MBX Biosciences (NasdaqGS:MBX) reported encouraging preliminary Phase 1 data for its lead obesity candidate, MBX 4291, with early weight loss signals and potential for once-monthly dosing.
The company introduced a new preclinical obesity program, MBX 5765, expanding its early stage pipeline.
MBX also shared positive proof-of-concept results from its Imapextide Phase 2a trial in post-bariatric hypoglycemia.
These updates arrive with MBX Biosciences trading at $37.5, after a very large 1-year...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.